TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01643018

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Description: In laparoscopy group three trocars is used. The first is 10 mm and inserted within the umbilicus for telescop, the second is 10 mm and inserted just below the xiphoid process, and third is 5 mm and inserted at the right upper quadrant of the abdomen.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open surgery
Description: -open surgery group describes the patients treated with traditional open surgery. In open surgery group a right subcostal incision is used.
Study: NCT01287416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Applied Suicide Intervention Skills Training
Description: Applied Suicide Intervention Skills Training (ASIST) is a 2-day, 14 hour suicide intervention skills training workshop.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resilience Retreat
Description: The Resilience Retreat is a 2-day, 14 hour session
Study: NCT03039088

Intervention type: OTHER
Intervention: Follow-up after 12 weeks after TNF alpha blockers initiation

Intervention type: OTHER
Intervention: Follow-up after 12 weeks after TNF alpha blockers initiation
Study: NCT01758302

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No physical task
Description: As a control, for 2 of the arms, participants are not asked to engage in a physical task
Study: NCT04659681

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PVI Guided fluid management during surgery for (PVI<12) colloid bolus will be given .
Description: PVI probe attached to finger in PVI Group

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CVP Guided Fluid management during surgery for CVP<10 cms H2O colloid bolus will be given
Description: Placement of central venous catheter
Study: NCT00963183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD5423 or placebo. Starting dose 8.4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for nebulisation, inhaled. Each subject will receive a single-dose.
Study: NCT04426409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tarivid ointment
Description: Vaseline ointment is applied to both noses.
Study: NCT01369277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04991532
Description: Single dose administration of PF-04991532 (100 mg, 300 mg and 750 mg) in tablet formulation under fasted condition.
Study: NCT01658124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02593526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bumetanide
Description: Diuretic
Study: NCT01369277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose administration of matching placebo in tablet formulation at the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04991532
Description: Single dose administration of PF-04991532 (300 mg and 750 mg) in tablet formulation under fasted condition.
Study: NCT02593526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bumetanide
Description: Diuretic

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cool Dialysate
Description: Cool dialysate (35°C)
Study: NCT02710071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Nebivolol 5mg then nebivolol 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Nebivolol 5mg then nebivolol 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 12.5 mg then hydrochlorothiazide 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 12.5 mg then hydrochlorothiazide 25 mg
Study: NCT02593526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cool Dialysate
Description: Cool dialysate (35°C)
Study: NCT01872143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation
Description: daily or twice-a-day administration of transcranial Direct Current Stimulation from a minimum of 10 session to a maximum of 20
Study: NCT03424291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib plus chemoradiation
Description: Apatinib 500 mg qd po Taxus + platinum or 5FU + platinum (drug dose reference to clinical) palliative radiotherapy dose ≥ 40Gy and radical radiotherapy dose (60-70Gy)
Study: NCT01270048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mild-ex-gwarip
Description: three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
Study: NCT01136538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir Hydrochloride
Description: Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir Hydrochloride
Description: Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
Study: NCT00863525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: odanacatib
Description: A single oral dose of 100 mg odanacatib administered with a light meal in one treatment period and without a meal in the other treatment period. There will be 10 days between treatment periods.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: A single oral dose of Placebo to odanacatib administered with a light meal in one treatment period and without a meal in the other treatment period. There will be 10 days between treatment periods.
Study: NCT03290534

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CivaSheet
Description: implanting CivaSheet for localized radiation dose delivery
Study: NCT02696811

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: White carrots
Description: White carrots contain compounds called polyacetylenes, including falcarinol, falcarindiol and falcarindiol-3-acetate.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oat biscuits
Description: The 3 oat biscuits contain the same amount of fibre and sugar as the white carrot but without the polyacetylenes.
Study: NCT03104790

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluenz Tetra (The two groups are defined by immunisation history, all receive the same intervention in the study)
Description: live attenuated influenza vaccine (LAIV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluenz Tetra (The two groups are defined by immunisation history, all receive the same intervention in the study)
Description: live attenuated influenza vaccine (LAIV)
Study: NCT02729896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab [TECENTRIQ]
Description: Atezolizumab will be administered by intravenous (IV) infusion at a flat dose of 1200 milligram (mg) every 3 weeks (Q3W) on Day 1 of Cycles 2-6, given in 21-day cycles during induction treatment.~NOTE: Atezolizumab treatment has been discontinued in all participants currently on study treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab [TECENTRIQ]
Description: Atezolizumab will be administered by intravenous (IV) infusion at a flat dose of 1200 milligram (mg) every 3 weeks (Q3W) on Day 1 of Cycles 2-6, given in 21-day cycles during induction treatment.~NOTE: Atezolizumab treatment has been discontinued in all participants currently on study treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered by IV infusion at a flat dose of 1000 mg on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-6, given in 21-day cycles during induction treatment, and on Day 1 of every other month during maintenance treatment (1 cycle=21 days; infusion rate starts at 50 mg/hour (hr) and increases every 30 min to a maximum of 400 mg/hr).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered by IV infusion at a flat dose of 1000 mg on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-6, given in 21-day cycles during induction treatment, and on Day 1 of every other month during maintenance treatment (1 cycle=21 days; infusion rate starts at 50 mg/hour (hr) and increases every 30 min to a maximum of 400 mg/hr).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Polatuzumab vedotin will be administered by IV infusion. For relapsed or refractory FL either 1.4 mg/kilogram (kg) or 1.8 mg/kg (dose-escalation phase) and at RP2D (dose-expansion phase) on Day 1 of Cycles 1-6 will be given in 21-day cycles during induction treatment. For relapsed or refactory DLBCL, 1.8 mg/kg will be given during run-in phase and either 1.8 mg/kg or 1.4 mg/kg during the expansion phase (1 cycle=21 days; infusion rate starts with 90 min and decreases to 30 min).
Study: NCT00943150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade
Description: The PEAK PlasmaBlade will be used for the abdominoplasty procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: The scalpel and electrocautery will be used for the abdominoplasty procedure.
Study: NCT03328871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 Laser
Description: Fractional Carbon Dioxide Laser will be treated once every three months for 2 times.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nanofat grafting
Description: Nanofat grafting will be applied once every three months for 2 times.
Study: NCT02729896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Polatuzumab vedotin will be administered by IV infusion. For relapsed or refractory FL either 1.4 mg/kilogram (kg) or 1.8 mg/kg (dose-escalation phase) and at RP2D (dose-expansion phase) on Day 1 of Cycles 1-6 will be given in 21-day cycles during induction treatment. For relapsed or refactory DLBCL, 1.8 mg/kg will be given during run-in phase and either 1.8 mg/kg or 1.4 mg/kg during the expansion phase (1 cycle=21 days; infusion rate starts with 90 min and decreases to 30 min).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Polatuzumab vedotin will be administered by IV infusion. For relapsed or refractory FL either 1.4 mg/kilogram (kg) or 1.8 mg/kg (dose-escalation phase) and at RP2D (dose-expansion phase) on Day 1 of Cycles 1-6 will be given in 21-day cycles during induction treatment. For relapsed or refactory DLBCL, 1.8 mg/kg will be given during run-in phase and either 1.8 mg/kg or 1.4 mg/kg during the expansion phase (1 cycle=21 days; infusion rate starts with 90 min and decreases to 30 min).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered by IV infusion at 375 mg/m˄2 on Day 1 of Cycles 1-6 during induction treatment (1 cycle-21 days; infusion rate starts with 50 mg/hr and increases every 30 min to a maximum of 400 mg/hr).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered by IV infusion at 375 mg/m˄2 on Day 1 of Cycles 1-6 during induction treatment (1 cycle-21 days; infusion rate starts with 50 mg/hr and increases every 30 min to a maximum of 400 mg/hr).
Study: NCT00372788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: oral vial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: oral
Study: NCT04578470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Daily 2000 IU cholecalciferol(two tablets) for 13 weeks,and daily 1000 IUcholecalciferol(1 tablet) foranother 13 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two tablets daily for 13weeks then 1 tablet daily for13 weeks
Study: NCT03328871

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) Injection
Description: PRP Injection will be applied once a month for 6 times.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) Injection
Description: PRP Injection will be applied once a month for 6 times.
Study: NCT01663285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Cisplatin and Gemcitabine
Description: Cisplatin 70 mg/m2 through IV for 60 minutes on day 1 of each cycle. Gemcitabine 1,000 mg/m2 IV for 30 minutes on days 1 and 8 during each cycle. Treatment is expected to continue for up to 4 cycles. Chemotherapy will be followed by radical nephroureterectomy within 6 weeks (+/- 2 weeks) from the last date of chemotherapy.
Study: NCT02103192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-Oxidant Drink
Study: NCT01101009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril + amlodipine + if necessary, hydrochlorothiazide
Description: Two perindopril 4 mg tablets + 1 amlodipine 10 mg tablet + placebo tablet matching the olmesartan/amlodipine tablet. All tablets are taken once daily. The duration of administration of perindopril tablets and placebo is 24 weeks. The duration of administration of amlodipine tablets is 24-26 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olmesartan/amlodipine + hydrochlorothiazide, if necessary.
Description: olmesartan/amlodipine tablets 40 mg/10 mg, + placebo tablets matching the perindopril tablet and amlodipine tablet. All tablets are taken once daily for 24 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary
Study: NCT01721525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib, Ribavirin, and weekly carboplatin/paclitaxel
Description: Patients will receive oral daily afatinib (days 1 - 21, per dose escalation scheme) plus daily oral ribavirin (days 1- 21) and paclitaxel (80 mg/m2 intravenously, days 1 and 8) + carboplatin (AUC 1.5 intravenously, days 1 and 8) of a 21-day cycle. Ribavirin will be administered according to standard weight-based dosing for this drug (1). Subjects ≤75 kg receive Ribavirin 400 mg PO qAM and 600 mg PO qPM (= 1000 mg/day). Subjects \> 75 kg receive Ribavirin 600 mg PO BID (=1200 mg/day). During the Dose Escalation portion of the study (Part 1), research bloodwork for pharmacokinetics is performed on days 1 and 8 of Cycle 1 only.
Study: NCT02028000

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insorb staples skin closure
Description: Patients will be randomized to Insorb staples skin closure and compared to Monocryl and Vicryl group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insorb staples skin closure
Description: Patients will be randomized to Insorb staples skin closure and compared to Monocryl and Vicryl group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monocryl skin closure
Description: Patients will be randomized to Monocryl skin closure and compared to Insorb skin closure and Vicryl skin closure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monocryl skin closure
Description: Patients will be randomized to Monocryl skin closure and compared to Insorb skin closure and Vicryl skin closure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl skin closure
Description: Patients will be randomized to Vicryl skin closure and compared to Insorb and Monocryl skin closure groups.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl skin closure
Description: Patients will be randomized to Vicryl skin closure and compared to Insorb and Monocryl skin closure groups.
Study: NCT03577158

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop controller without exercise mitigation module
Description: On the second arm, participants will receive Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration without a mitigation mode, based on subcutaneous continuous glucose monitoring (Second arm, Closed-loop study without mitigation module).~Commercial insulin infusion systems and continuous glucose monitoring devices will be used.
Study: NCT02506647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gan & Lee insulin glargine followed by Lantus
Description: 0.4 IU/kg Gan \& Lee insulin glargine injection SC, Lantus 0.4 IU/kg injection SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus followed by Gan & Lee insulin glargine
Description: Lantus 0.4 IU/kg injection SC, 0.4 IU/kg Gan \& Lee insulin glargine injection SC,
Study: NCT00780026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin
Description: bolus or infusion 80 to 110 mg/dl
Study: NCT02417090

Intervention type: DRUG
Intervention: Insulin
Description: Pregnant women who used insulin to treat gestational diabetes

Intervention type: DRUG
Intervention: Metformin
Description: Pregnant women who used metformin to treat gestational diabetes
Study: NCT03213756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isometric exercises using Hand grip and elastic bands
Description: * Isometric exercises using hand-grip. This exercise consists of two sets of 30 hand-grip contractions with the hand of the upper arm candidate for AVF (in case of doubts about the most appropriate arm for AVF the exercise will be performed with both arms). The patient will rest one minute every 10 contractions and 5 minutes between both sets. The patient will repeat this protocol twice a day, morning and night (Approximately 15 minutes each session). The contraction intensity will start with half of the maximum force obtained by dynamometry and will be increased or decreased to be placed on an effort intensity 2-3 in the Borg scale.~* Isometric exercise using elastic bands. At noon the patient will perform a slow contraction session using elastic band with 20 slow repetitions with the arm in flexion and 20 repetitions with the arm in extension. (Total duration: less than 10 minutes)
Study: NCT01875575

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose 25g

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose 10g
Study: NCT01022788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based counselling
Study: NCT03577158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open-loop insulin infusion system
Description: Standard subcutaneous insulin infusion based on the individual insulin sensibility. Commercial insulin infusion systems and continuous subcutaneous glucose monitoring devices will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open-loop insulin infusion system
Description: Standard subcutaneous insulin infusion based on the individual insulin sensibility. Commercial insulin infusion systems and continuous subcutaneous glucose monitoring devices will be used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open-loop insulin infusion system
Description: Standard subcutaneous insulin infusion based on the individual insulin sensibility. Commercial insulin infusion systems and continuous subcutaneous glucose monitoring devices will be used.
Study: NCT04340128

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meglumine antimoniate
Description: Intra-lesional injection once a week, 0.1/cm2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meglumine antimoniate
Description: Intra-lesional injection twice a week, 0.1/cm2
Study: NCT04041765

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IgM-enriched IVIG
Description: Contains human plasma protein 50mg/ml. With composition of Immunoglobulin M (IgM) 6mg, Immunoglobulin A (IgA) 6mg, Immunoglobulin G (IgG) 38mg (IgG subcl. approx. 63 % IgG1, 26 % IgG2, 4 % IgG3 and 7 % IgG4), Glucose monohydrate, sodium chloride, water for injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IgM-enriched IVIG
Description: Contains human plasma protein 50mg/ml. With composition of Immunoglobulin M (IgM) 6mg, Immunoglobulin A (IgA) 6mg, Immunoglobulin G (IgG) 38mg (IgG subcl. approx. 63 % IgG1, 26 % IgG2, 4 % IgG3 and 7 % IgG4), Glucose monohydrate, sodium chloride, water for injections
Study: NCT01684566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: episil(R)
Description: episil® is a lipid-based liquid that spreads onto mucosal surfaces and transforms into a protective, strongly bioadhesive FluidCrystal® film after intraoral administration.

Intervention type: OTHER
Group type: OTHER
Intervention: Oral hygiene procedures
Description: Oral hygiene by using toothbrush, toothpaste, lip balm and dental floss (if available)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral hygiene procedures
Description: Oral hygiene by using toothbrush, toothpaste, lip balm and dental floss (if available)
Study: NCT03007654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mediclore
Description: apply medical device fully around intrauterine surgery area

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adept
Description: apply medical device fully around intrauterine surgery area
Study: NCT02408666

Intervention type: OTHER
Group type: OTHER
Intervention: Interview
Study: NCT00026104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study: NCT00860314

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: external electrical cardioversion (with antero-posterior electrode position)
Description: external biphasic electrical cardioversion with step-up-protocol of 50-75-100-150-200 Joules if necessary with antero-posterior electrode position until restoration of normal sinus rhythm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: external electrical cardioversion (with antero-lateral electrode position)
Description: external biphasic electrical cardioversion with step-up protocol of 50-75-100-150-200 Joules if necessary with antero-lateral electrode position until restoration of normal sinus rhythm